At the time of writing, Larimar Therapeutics Inc [LRMR] stock is trading at $8.90, up 14.54%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The LRMR shares have gain 11.67% over the last week, with a monthly amount glided 16.34%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Larimar Therapeutics Inc [NASDAQ: LRMR] stock has seen the most recent analyst activity on September 04, 2024, when Robert W. Baird initiated its Outperform rating and assigned the stock a price target of $16. Previously, Leerink Partners started tracking the stock with Outperform rating on April 03, 2024, and set its price target to $25. On November 17, 2023, upgrade upgraded it’s rating to Buy but maintained its price target of $4.50 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $12 on October 19, 2022. William Blair downgraded its rating to a Mkt Perform. In a note dated February 01, 2021, William Blair initiated an Outperform rating and provided a target price of $29 on this stock.
For the past year, the stock price of Larimar Therapeutics Inc fluctuated between $2.18 and $13.68. Currently, Wall Street analysts expect the stock to reach $14.5 within the next 12 months. Larimar Therapeutics Inc [NASDAQ: LRMR] shares were valued at $8.90 at the most recent close of the market. An investor can expect a potential return of 62.92% based on the average LRMR price forecast.
Analyzing the LRMR fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -0.38 and Total Capital is -0.3. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.04 points at the first support level, and at 7.17 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.40, and for the 2nd resistance point, it is at 9.89.
Ratios To Look Out For
It is important to note that Larimar Therapeutics Inc [NASDAQ:LRMR] has a current ratio of 10.93. Further, the Quick Ratio stands at 10.93, while the Cash Ratio is 1.53.
Transactions by insiders
Recent insider trading involved Hamilton Thomas Edward, Director, that happened on Feb 16 ’24 when 57208.0 shares were purchased. Director, Flynn James E completed a deal on Feb 16 ’24 to buy 4.29 million shares. Meanwhile, Director THOMAS FRANK E bought 2000.0 shares on Feb 14 ’24.
